bupropion has been researched along with Chronic Disease in 24 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was conducted to evaluate the effect of bupropion sustained-release (SR) on smoking cessation in patients with chronic posttraumatic stress disorder (PTSD)." | 9.09 | A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. ( Beckham, JC; Feldman, ME; Hertzberg, MA; Moore, SD, 2001) |
| "Bupropion is a specific inhibitor of neuronal noradrenaline reuptake and a weak inhibitor of dopamine reuptake, which shows some promise in the treatment of neuropathic pain." | 6.46 | Bupropion for the treatment of neuropathic pain. ( Moradimehr, A; Shah, TH, 2010) |
| "Participants were weight-concerned women (n = 349) ages 18-65 enrolled in a randomized, double-blind, placebo-controlled smoking cessation trial of bupropion and cognitive behavioral therapy." | 5.20 | A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms? ( Cheng, Y; Creswell, KG; Levine, MD, 2015) |
| "This study was conducted to evaluate the effect of bupropion sustained-release (SR) on smoking cessation in patients with chronic posttraumatic stress disorder (PTSD)." | 5.09 | A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. ( Beckham, JC; Feldman, ME; Hertzberg, MA; Moore, SD, 2001) |
| "Guidance in England and Wales recommends that nicotine replacement therapies (NRTs), varenicline or bupropion should be offered for smoking cessation support." | 3.80 | General practitioner prescribing of single and combination nicotine replacement therapy in the UK: a retrospective database study. ( Anderson, P; Johnson, M; Lockhart, I, 2014) |
| " Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use." | 3.79 | Therapies for obesity and medication-associated weight gain. ( Howland, RH, 2013) |
| "The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy." | 2.77 | Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Bupropion SR in the treatment of PTSD had no significant effect in the current sample." | 2.73 | A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. ( Becker, ME; Beckham, JC; Bukenya, DS; Dennis, MF; Hertzberg, MA; Moore, SD, 2007) |
| "Bupropion is a specific inhibitor of neuronal noradrenaline reuptake and a weak inhibitor of dopamine reuptake, which shows some promise in the treatment of neuropathic pain." | 2.46 | Bupropion for the treatment of neuropathic pain. ( Moradimehr, A; Shah, TH, 2010) |
| "Treating tobacco dependence is one of the most cost-effective actions in health care." | 1.38 | Strategies to help a smoker who is struggling to quit. ( Rigotti, NA, 2012) |
| "All subjects received periodontal treatment and smoking cessation advice as part of an individual, patient-based programme provided by dental hygienists trained in smoking cessation counselling." | 1.33 | Smoking cessation advice for patients with chronic periodontitis. ( Heasman, L; Heasman, PA; Nasry, HA; Preshaw, PM; Stacey, F; Swan, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, C | 1 |
| Wu, L | 1 |
| Liu, Q | 1 |
| An, H | 1 |
| Jiang, B | 1 |
| Zuo, F | 1 |
| Zhang, L | 1 |
| He, Y | 1 |
| Howland, RH | 2 |
| Warden, D | 2 |
| Trivedi, MH | 4 |
| Carmody, T | 1 |
| Toups, M | 1 |
| Zisook, S | 2 |
| Lesser, I | 1 |
| Myers, A | 1 |
| Kurian, KR | 1 |
| Morris, D | 1 |
| Rush, AJ | 3 |
| Johnson, M | 1 |
| Anderson, P | 1 |
| Lockhart, I | 1 |
| Creswell, KG | 1 |
| Cheng, Y | 1 |
| Levine, MD | 1 |
| Wind, LA | 1 |
| Chavannes, NH | 1 |
| Kaper, J | 1 |
| Frijling, BD | 1 |
| van der Laan, JR | 1 |
| Wiersma, T | 1 |
| Goudswaard, AN | 1 |
| Klein, DN | 1 |
| Arnow, BA | 1 |
| Barkin, JL | 1 |
| Dowling, F | 1 |
| Kocsis, JH | 1 |
| Leon, AC | 1 |
| Manber, R | 1 |
| Rothbaum, BO | 1 |
| Wisniewski, SR | 3 |
| Joy, MS | 1 |
| Frye, RF | 1 |
| Stubbert, K | 1 |
| Brouwer, KR | 1 |
| Falk, RJ | 1 |
| Kharasch, ED | 1 |
| Shah, TH | 1 |
| Moradimehr, A | 1 |
| Davis, LL | 1 |
| Pilkinton, P | 1 |
| Gaynes, BN | 1 |
| Balasubramani, GK | 1 |
| Fava, M | 2 |
| Sung, SC | 1 |
| Haley, CL | 1 |
| Nierenberg, AA | 1 |
| Morris, DW | 1 |
| Kurian, BT | 1 |
| Rigotti, NA | 1 |
| Kast, RE | 1 |
| Altschuler, EL | 1 |
| Katz, J | 1 |
| Pennella-Vaughan, J | 1 |
| Hetzel, RD | 1 |
| Kanazi, GE | 1 |
| Dworkin, RH | 1 |
| Nasry, HA | 1 |
| Preshaw, PM | 1 |
| Stacey, F | 1 |
| Heasman, L | 1 |
| Swan, M | 1 |
| Heasman, PA | 1 |
| Becker, ME | 1 |
| Hertzberg, MA | 2 |
| Moore, SD | 2 |
| Dennis, MF | 1 |
| Bukenya, DS | 1 |
| Beckham, JC | 2 |
| Tyndale, R | 1 |
| Bras, M | 1 |
| Davidson, JR | 1 |
| France, RD | 1 |
| Pinsker, W | 1 |
| Cañive, JM | 1 |
| Clark, RD | 1 |
| Calais, LA | 1 |
| Qualls, C | 1 |
| Tuason, VB | 1 |
| Fatemi, SH | 1 |
| Emamian, ES | 1 |
| Kist, DA | 1 |
| Feldman, ME | 1 |
| Wright, G | 1 |
| Galloway, L | 1 |
| Kim, J | 1 |
| Dalton, M | 1 |
| Miller, L | 1 |
| Stern, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
2 reviews available for bupropion and Chronic Disease
| Article | Year |
|---|---|
Bupropion for the treatment of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Bupropion; Chronic Disease; Controlled Clinical Trials as Topic; Dopamine | 2010 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami | 2007 |
8 trials available for bupropion and Chronic Disease
| Article | Year |
|---|---|
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
Topics: Adult; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Diso | 2014 |
A test of the stress-buffering model of social support in smoking cessation: is the relationship between social support and time to relapse mediated by reduced withdrawal symptoms?
Topics: Adolescent; Adult; Aged; Bupropion; Chronic Disease; Cognitive Behavioral Therapy; Counseling; Depre | 2015 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive | 2012 |
The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Comorbidity; | 2012 |
A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Cross-Over Studies; Del | 2005 |
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Bupropion; Chronic | 2007 |
A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Delayed-Action Preparat | 2001 |
Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Body Weight; Bupropion; Chroni | 1985 |
14 other studies available for bupropion and Chronic Disease
| Article | Year |
|---|---|
Evaluation of smoking cessation intervention in patients with chronic diseases in smoking cessation clinics.
Topics: Adult; Bupropion; Chronic Disease; Combined Modality Therapy; Counseling; Follow-Up Studies; Humans; | 2017 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined | 2013 |
General practitioner prescribing of single and combination nicotine replacement therapy in the UK: a retrospective database study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Bupropion; Chronic Disease; Drug Therapy, | 2014 |
[Summary of the practice guideline 'Smoking cessation' from the Dutch College of General Practitioners].
Topics: Bupropion; Chronic Disease; Family Practice; Female; Humans; Male; Motivation; Netherlands; Nicotine | 2008 |
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropi | 2009 |
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antidepressive Agents, Second-Gen | 2010 |
Strategies to help a smoker who is struggling to quit.
Topics: Behavior Therapy; Benzazepines; Bupropion; Chronic Disease; Counseling; Disease Management; Dopamine | 2012 |
Bupropion and chronic aphthous ulceration.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Depressive Disorder; Hu | 2005 |
Smoking cessation advice for patients with chronic periodontitis.
Topics: Adult; Breath Tests; Bupropion; Carbon Monoxide; Central Nervous System Stimulants; Chronic Disease; | 2006 |
Drug addiction: a critical problem calling for novel solutions.
Topics: Benzazepines; Buprenorphine; Bupropion; Chronic Disease; Financing, Government; Genetic Testing; Har | 2008 |
Bupropion in chronic low back pain.
Topics: Adult; Back Pain; Bupropion; Chronic Disease; Female; Humans; Male; Pain Measurement; Treatment Outc | 1994 |
Treatment of headache with bupropion.
Topics: Bupropion; Chronic Disease; Dopamine Uptake Inhibitors; Headache; Humans; Recurrence | 1998 |
Bupropion treatment in veterans with posttraumatic stress disorder: an open study.
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Combat Disorders; Follow | 1998 |
Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Cyclohexanols; Depressi | 1999 |